Geographic Atrophy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech
Some of the major pharma and biotech companies such as Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Gyroscope Therapeutics, and others are actively working in the Geographic Atrophy Market.
DelveInsight’s “Geographic Atrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Geographic Atrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Geographic Atrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geographic Atrophy: An Overview
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration, also called age-related macular degeneration (AMD or ARMD), is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet.” According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.
Geographic Atrophy is a progressive, irreversible, and blinding disease affecting both eyes. Nearly two-thirds of geographic atrophy cases are reported in people 80 and older. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.
Geographic Atrophy Market Key Facts
-
In the 7MM, the total diagnosed cases of Geographic Atrophy were 2,822,853 cases in 2021. These cases are expected to grow with a significant CAGR in the study period 2019–2032.
-
Globally, more than 5 million people are affected by Geographic Atrophy. Also, as per the published study by the GER group, the global prevalence of Geographic Atrophy is 0.66% in all ages, but it occurs in 0.34% of 65–74 years old, 1.3% for 75–84, and 4.4% over 85 years old.
-
According to the research study of Friedman et al., 2004, the overall prevalence rate of geographic atrophy in the US population 40 years and older was 0.81 per 100 people.
-
As per Boyer et al. (2017), approximately 973,000 people in the United States and approx. five million globally have Geographic Atrophy in at least one eye.
-
As per National Institute for Health and Care Excellence (NICE) 2019, the prevalence rate of Geographic Atrophy in the United Kingdom was found to be between 1.3%-6.7%.
-
According to Y. Sakurada (2016), the prevalence of Geographic Atrophy was 6.6% among elderly Japanese with AMD.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Geographic Atrophy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Geographic Atrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Geographic Atrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Geographic Atrophy Epidemiology, Segmented as –
-
Total Prevalent Cases of Geographic Atrophy in the 7MM [2019–2032]
-
Total Geographic Atrophy Cases by Visual Impairment in the 7MM [2019–2032]
-
Total Diagnosed Cases of Geographic Atrophy in the 7MM [2019–2032]
-
Total Diagnosed Cases of Geographic Atrophy by Age Distribution in the 7MM [2019–2032]
-
Treated cases of Geographic Atrophy in the 7MM [2019–2032]
Geographic Atrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Geographic Atrophy market or expected to be launched during the study period. The analysis covers the Geographic Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Geographic Atrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Geographic Atrophy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market
Geographic Atrophy Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Geographic Atrophy. Currently, IVERIC bio is leading the therapeutics market with its Geographic Atrophy drug candidates in the most advanced stage of clinical development.
The Leading Players in the Geographic Atrophy Therapeutics Market Include:
Alexion, Alkeus Pharmaceuticals, Annexon Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma Inc, Boehringer Ingelheim, Catalyst Biosciences, Cell Cure Neurosciences LTD, Eyevensys, Gemini Therapeutics, Genentech, Gyroscope Therapeutics Limited, Hemera Biosciences, Ionis Pharmaceuticals, IVERIC bio, Iveric Bio (formerly Ophthotech Corporation), Nanoscope Therapeutics, Inc., NGM Biopharmaceuticals, Novartis, ONL Therapeutics, Regenerative Patch Technologies, LLC, Stealth BioTherapeutics Inc., and others.
Geographic Atrophy Emerging and Marketed Drugs Covered in the Report Include:
-
Pegcetacoplan: Apellis Pharmaceuticals
-
CPCB-RPE1: Regenerative Patch Technologies
-
Elamipretide: Stealth BioTherapeutics
-
IONIS-FB-LRx: Ionis Pharmaceuticals/ Roche
-
NGM621: NGM Biopharmaceuticals
-
OpRegen: CellCure Neurosciences/ Lineage Cell Therapeutics/ Roche
-
PPY988/GT005: Novartis
-
RO7171009; RG6147: Genentech/ Roche
-
RPESC-RPE-4W: Luxa Biotechnology
-
Zimura: IVERIC bio
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Geographic Atrophy Competitive Intelligence Analysis
4. Geographic Atrophy Market Overview at a Glance
5. Geographic Atrophy Disease Background and Overview
6. Geographic Atrophy Patient Journey
7. Geographic Atrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Geographic Atrophy Unmet Needs
10. Key Endpoints of Geographic Atrophy Treatment
11. Geographic Atrophy Marketed Products
12. Geographic Atrophy Emerging Drugs and Latest Therapeutic Advances
13. Geographic Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Geographic Atrophy Market Outlook (In US, EU5, and Japan)
16. Geographic Atrophy Access and Reimbursement Overview
17. KOL Views on the Geographic Atrophy Market
18. Geographic Atrophy Market Drivers
19. Geographic Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
 – DelveInsight | Key Companies – Ionis, Roche, NGM Biopharma, Apellis Pharma, Novartis, Genentech){kind=link}